The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Neurogene Inc shares valued at $76,247 were sold by Cvijic Christine Mikail on Mar 13 ’25. At $16.94 per share, Cvijic Christine Mikail sold 4,501 shares. The insider’s holdings dropped to 72,343 shares worth approximately $0.83 million following the completion of this transaction.
Also, Samsara BioCapital GP, LLC purchased 48,770 shares, netting a total of over 1,259,623 in proceeds. Following the buying of shares at $25.83 each, the insider now holds 1,717,127 shares.
Before that, Cvijic Christine Mikail had added 24,000 shares to its account. In a trade valued at $491,400, the President and CFO bought Neurogene Inc shares for $20.48 each. Upon closing the transaction, the insider’s holdings increased to 24,000 shares, worth approximately $0.88 million.
As published in their initiating research note from BMO Capital Markets on June 27, 2024, Neurogene Inc [NGNE] has been an Outperform and the price target has been revised to $65. Analysts at Robert W. Baird started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid June. As of April 29, 2024, Leerink Partners has initiated its “an Outperform” rating for NGNE. Earlier on March 21, 2024, William Blair initiated its rating. Their recommendation was “an Outperform” for NGNE stock.
Analyzing NGNE Stock Performance
During the last five days, there has been a surge of approximately 28.09%. Over the course of the year, Neurogene Inc shares have dropped approximately -49.74%. Shares of the company reached a 52-week high of $26.48 on 02/06/25 and a 52-week low of $6.88 on 04/08/25. A 50-day SMA is recorded $15.02, while a 200-day SMA reached $29.96.
Support And Resistance Levels for Neurogene Inc (NGNE)
According to the 24-hour chart, there is a support level at 10.79, which, if violated, would cause prices to drop to 10.08. In the upper region, resistance lies at 11.87. The next price resistance is at 12.24. RSI (Relative Strength Index) is 46.39 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.28, which suggests the price will increase in the coming days. Percent R is at 33.67%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Neurogene Inc (NGNE)?
On January 08, 2024, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $45.
